| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelium, Vascular | 37 | 2014 | 520 | 6.230 |
Why?
|
| Coronary Vessels | 29 | 2013 | 541 | 5.230 |
Why?
|
| Endothelial Cells | 26 | 2014 | 521 | 4.900 |
Why?
|
| Muscle, Smooth, Vascular | 17 | 2012 | 238 | 2.830 |
Why?
|
| Pancreatic Neoplasms | 37 | 2013 | 691 | 2.380 |
Why?
|
| Nitric Oxide Synthase Type III | 23 | 2014 | 219 | 2.380 |
Why?
|
| Vasodilation | 17 | 2012 | 191 | 2.190 |
Why?
|
| Superoxides | 25 | 2012 | 151 | 2.180 |
Why?
|
| Ritonavir | 10 | 2011 | 54 | 2.140 |
Why?
|
| Homocysteine | 10 | 2008 | 122 | 2.010 |
Why?
|
| HIV Protease Inhibitors | 9 | 2012 | 54 | 1.570 |
Why?
|
| Thymosin | 6 | 2013 | 24 | 1.560 |
Why?
|
| Cell Movement | 11 | 2013 | 836 | 1.550 |
Why?
|
| MicroRNAs | 8 | 2013 | 835 | 1.460 |
Why?
|
| Swine | 30 | 2012 | 1192 | 1.390 |
Why?
|
| Neoplasms | 16 | 2013 | 2789 | 1.380 |
Why?
|
| Oxidative Stress | 18 | 2012 | 805 | 1.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2013 | 681 | 1.300 |
Why?
|
| Cells, Cultured | 30 | 2013 | 3039 | 1.190 |
Why?
|
| Myocytes, Smooth Muscle | 7 | 2012 | 158 | 1.120 |
Why?
|
| Cell Proliferation | 19 | 2013 | 2290 | 1.080 |
Why?
|
| Tyrosine | 5 | 2012 | 150 | 1.070 |
Why?
|
| Atherosclerosis | 9 | 2012 | 914 | 1.060 |
Why?
|
| Pulmonary Artery | 5 | 2011 | 443 | 1.050 |
Why?
|
| Animals | 96 | 2013 | 34046 | 1.040 |
Why?
|
| Resistin | 4 | 2012 | 34 | 1.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2013 | 1895 | 1.010 |
Why?
|
| Precision Medicine | 4 | 2013 | 319 | 1.010 |
Why?
|
| RNA, Messenger | 28 | 2011 | 2815 | 0.990 |
Why?
|
| Vascular Diseases | 6 | 2010 | 168 | 0.960 |
Why?
|
| Cyclophilin A | 3 | 2011 | 16 | 0.950 |
Why?
|
| Foam Cells | 3 | 2009 | 21 | 0.900 |
Why?
|
| Antioxidants | 12 | 2013 | 335 | 0.890 |
Why?
|
| Nitric Oxide Synthase | 12 | 2009 | 186 | 0.860 |
Why?
|
| Vasomotor System | 4 | 2009 | 25 | 0.810 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 5 | 2011 | 95 | 0.770 |
Why?
|
| Curcumin | 4 | 2005 | 41 | 0.760 |
Why?
|
| Protein S | 2 | 2013 | 10 | 0.750 |
Why?
|
| Cholangiocarcinoma | 2 | 2013 | 106 | 0.730 |
Why?
|
| Down-Regulation | 16 | 2013 | 698 | 0.730 |
Why?
|
| Humans | 132 | 2014 | 124867 | 0.720 |
Why?
|
| Neuropilins | 3 | 2005 | 9 | 0.720 |
Why?
|
| Neovascularization, Pathologic | 6 | 2011 | 240 | 0.710 |
Why?
|
| Cation Transport Proteins | 6 | 2013 | 93 | 0.700 |
Why?
|
| Bradykinin | 10 | 2012 | 59 | 0.690 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 4 | 2011 | 111 | 0.690 |
Why?
|
| C-Reactive Protein | 3 | 2007 | 428 | 0.670 |
Why?
|
| Ginsenosides | 4 | 2012 | 21 | 0.660 |
Why?
|
| Lactosylceramides | 2 | 2009 | 7 | 0.650 |
Why?
|
| Glycoproteins | 3 | 2008 | 367 | 0.650 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 15 | 2010 | 1288 | 0.640 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2009 | 267 | 0.640 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2013 | 1692 | 0.630 |
Why?
|
| Gene Expression | 12 | 2013 | 1562 | 0.620 |
Why?
|
| Cardiovascular Diseases | 6 | 2014 | 1950 | 0.600 |
Why?
|
| Macrophages | 5 | 2012 | 618 | 0.590 |
Why?
|
| Tunica Intima | 6 | 2003 | 58 | 0.580 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2014 | 408 | 0.580 |
Why?
|
| In Vitro Techniques | 13 | 2011 | 970 | 0.580 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2010 | 24 | 0.580 |
Why?
|
| Nitric Oxide | 9 | 2014 | 445 | 0.580 |
Why?
|
| Arteriosclerosis | 4 | 2005 | 144 | 0.570 |
Why?
|
| Arteries | 6 | 2009 | 221 | 0.560 |
Why?
|
| Carotid Arteries | 5 | 2008 | 150 | 0.560 |
Why?
|
| Cell Line, Tumor | 26 | 2013 | 3343 | 0.560 |
Why?
|
| Cell Membrane Permeability | 2 | 2008 | 74 | 0.540 |
Why?
|
| Genomics | 4 | 2013 | 1502 | 0.520 |
Why?
|
| Cholesterol | 3 | 2013 | 537 | 0.510 |
Why?
|
| Oncogenes | 3 | 2013 | 167 | 0.510 |
Why?
|
| Coronary Artery Disease | 4 | 2009 | 790 | 0.510 |
Why?
|
| Neovascularization, Physiologic | 4 | 2014 | 209 | 0.500 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2005 | 93 | 0.500 |
Why?
|
| Lysophosphatidylcholines | 2 | 2005 | 13 | 0.500 |
Why?
|
| Cell Division | 13 | 2011 | 777 | 0.490 |
Why?
|
| Fasciola hepatica | 2 | 2013 | 6 | 0.490 |
Why?
|
| Cell Culture Techniques | 5 | 2009 | 280 | 0.490 |
Why?
|
| Thrombomodulin | 2 | 2005 | 24 | 0.480 |
Why?
|
| Peripheral Vascular Diseases | 4 | 2011 | 93 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2013 | 724 | 0.450 |
Why?
|
| Antigens, CD | 5 | 2009 | 422 | 0.440 |
Why?
|
| Adenocarcinoma | 8 | 2011 | 1023 | 0.440 |
Why?
|
| Hyperplasia | 10 | 2011 | 208 | 0.440 |
Why?
|
| Phosphofructokinase-1, Type C | 1 | 2013 | 8 | 0.440 |
Why?
|
| Thromboplastin | 1 | 2013 | 17 | 0.440 |
Why?
|
| RNA, Untranslated | 2 | 2011 | 113 | 0.430 |
Why?
|
| Stem Cells | 2 | 2011 | 693 | 0.430 |
Why?
|
| Receptors, Somatostatin | 4 | 2008 | 54 | 0.430 |
Why?
|
| Signal Transduction | 11 | 2011 | 4496 | 0.420 |
Why?
|
| Carotid Artery Injuries | 3 | 2008 | 40 | 0.420 |
Why?
|
| Blotting, Western | 10 | 2011 | 1101 | 0.420 |
Why?
|
| Endarterectomy | 3 | 1997 | 29 | 0.410 |
Why?
|
| Vasoconstriction | 3 | 2008 | 101 | 0.410 |
Why?
|
| Aorta | 5 | 2008 | 541 | 0.400 |
Why?
|
| Inflammation | 4 | 2009 | 1431 | 0.400 |
Why?
|
| Capillary Permeability | 2 | 2009 | 75 | 0.400 |
Why?
|
| Lysophospholipids | 1 | 2012 | 30 | 0.390 |
Why?
|
| Estradiol | 2 | 2005 | 531 | 0.390 |
Why?
|
| Aortic Aneurysm, Abdominal | 6 | 2008 | 449 | 0.380 |
Why?
|
| Heparin | 4 | 2009 | 226 | 0.380 |
Why?
|
| CD40 Ligand | 2 | 2010 | 64 | 0.380 |
Why?
|
| Immunohistochemistry | 10 | 2011 | 1691 | 0.380 |
Why?
|
| Apoptosis | 7 | 2013 | 1796 | 0.380 |
Why?
|
| Models, Biological | 4 | 2010 | 1458 | 0.380 |
Why?
|
| Stress, Mechanical | 4 | 2009 | 172 | 0.380 |
Why?
|
| Interleukin-6 | 6 | 2013 | 419 | 0.370 |
Why?
|
| Cholesterol Esters | 2 | 2008 | 15 | 0.370 |
Why?
|
| Gene Expression Regulation | 7 | 2013 | 2519 | 0.360 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2011 | 96 | 0.360 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2008 | 54 | 0.360 |
Why?
|
| GPI-Linked Proteins | 7 | 2013 | 100 | 0.360 |
Why?
|
| Recombinant Proteins | 8 | 2011 | 1392 | 0.360 |
Why?
|
| Autoantibodies | 1 | 2013 | 434 | 0.350 |
Why?
|
| Bile Duct Neoplasms | 1 | 2011 | 108 | 0.340 |
Why?
|
| Carotid Sinus | 1 | 2010 | 6 | 0.340 |
Why?
|
| Pressoreceptors | 1 | 2010 | 10 | 0.340 |
Why?
|
| HIV-1 | 3 | 2005 | 464 | 0.340 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2010 | 137 | 0.330 |
Why?
|
| Chemokine CCL11 | 1 | 2009 | 12 | 0.330 |
Why?
|
| Membrane Potential, Mitochondrial | 4 | 2012 | 51 | 0.330 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 671 | 0.330 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 63 | 0.330 |
Why?
|
| Blood Vessel Prosthesis | 6 | 2005 | 546 | 0.330 |
Why?
|
| Simian Immunodeficiency Virus | 5 | 2010 | 92 | 0.330 |
Why?
|
| Reactive Oxygen Species | 6 | 2013 | 484 | 0.320 |
Why?
|
| Blood Vessels | 2 | 2011 | 102 | 0.320 |
Why?
|
| Water-Electrolyte Balance | 1 | 2010 | 81 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2013 | 544 | 0.320 |
Why?
|
| Benzoxazines | 1 | 2009 | 24 | 0.320 |
Why?
|
| Isoflavones | 1 | 2009 | 45 | 0.320 |
Why?
|
| Disease Models, Animal | 15 | 2013 | 4351 | 0.320 |
Why?
|
| Chaperonin 60 | 1 | 2009 | 30 | 0.320 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2009 | 37 | 0.320 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 17 | 0.320 |
Why?
|
| Cell Lineage | 1 | 2011 | 337 | 0.320 |
Why?
|
| Adenosine Triphosphatases | 2 | 2013 | 200 | 0.320 |
Why?
|
| Transforming Growth Factor beta | 2 | 2011 | 459 | 0.310 |
Why?
|
| Capsaicin | 1 | 2009 | 18 | 0.310 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2008 | 10 | 0.310 |
Why?
|
| Tissue Engineering | 4 | 2010 | 177 | 0.310 |
Why?
|
| Serum Amyloid A Protein | 1 | 2008 | 29 | 0.310 |
Why?
|
| Molecular Biology | 1 | 2009 | 79 | 0.310 |
Why?
|
| Copper | 1 | 2009 | 59 | 0.310 |
Why?
|
| Blood Coagulation | 1 | 2009 | 123 | 0.310 |
Why?
|
| Ghrelin | 1 | 2008 | 53 | 0.300 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 5 | 2009 | 38 | 0.300 |
Why?
|
| Mice, Nude | 9 | 2013 | 711 | 0.300 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2010 | 143 | 0.300 |
Why?
|
| Microarray Analysis | 1 | 2009 | 229 | 0.300 |
Why?
|
| Gene Silencing | 5 | 2013 | 235 | 0.300 |
Why?
|
| Lipoproteins, LDL | 1 | 2008 | 120 | 0.300 |
Why?
|
| Ginkgo biloba | 2 | 2008 | 13 | 0.290 |
Why?
|
| Nitroprusside | 5 | 2009 | 47 | 0.290 |
Why?
|
| Somatostatin | 2 | 2005 | 71 | 0.290 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2008 | 127 | 0.290 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2010 | 129 | 0.290 |
Why?
|
| Congresses as Topic | 1 | 2009 | 173 | 0.290 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 17 | 0.290 |
Why?
|
| Smad Proteins | 1 | 2008 | 43 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2013 | 618 | 0.290 |
Why?
|
| Ceramides | 1 | 2007 | 39 | 0.280 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 46 | 0.280 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 689 | 0.280 |
Why?
|
| Models, Animal | 5 | 2009 | 465 | 0.280 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2008 | 107 | 0.280 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 38 | 0.280 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 129 | 0.280 |
Why?
|
| Phosphorylation | 7 | 2010 | 1613 | 0.280 |
Why?
|
| Mice | 25 | 2013 | 17573 | 0.280 |
Why?
|
| Cell Differentiation | 5 | 2009 | 1884 | 0.270 |
Why?
|
| Peptides | 2 | 2014 | 798 | 0.270 |
Why?
|
| Femoral Artery | 5 | 2013 | 194 | 0.270 |
Why?
|
| Plant Extracts | 2 | 2008 | 120 | 0.270 |
Why?
|
| Polytetrafluoroethylene | 6 | 2005 | 84 | 0.270 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 189 | 0.270 |
Why?
|
| MAP Kinase Signaling System | 5 | 2013 | 313 | 0.260 |
Why?
|
| Cell Line | 7 | 2013 | 2746 | 0.260 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2011 | 994 | 0.260 |
Why?
|
| Arteriovenous Shunt, Surgical | 4 | 2005 | 101 | 0.250 |
Why?
|
| NF-kappa B | 5 | 2013 | 455 | 0.250 |
Why?
|
| Hypoxia | 1 | 2007 | 246 | 0.250 |
Why?
|
| Muscle Relaxation | 2 | 2003 | 16 | 0.250 |
Why?
|
| Hyperhomocysteinemia | 1 | 2005 | 38 | 0.250 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2005 | 280 | 0.250 |
Why?
|
| RNA, Small Interfering | 5 | 2011 | 660 | 0.250 |
Why?
|
| Biomedical Engineering | 1 | 2005 | 28 | 0.250 |
Why?
|
| Superoxide Dismutase | 3 | 2012 | 137 | 0.250 |
Why?
|
| Hormones, Ectopic | 1 | 2005 | 8 | 0.250 |
Why?
|
| Cytokines | 7 | 2012 | 1289 | 0.240 |
Why?
|
| Selenomethionine | 3 | 2012 | 14 | 0.240 |
Why?
|
| Cyclophilins | 1 | 2005 | 19 | 0.240 |
Why?
|
| Defensins | 1 | 2005 | 6 | 0.240 |
Why?
|
| Membrane Proteins | 4 | 2009 | 1527 | 0.240 |
Why?
|
| Methionine | 1 | 2005 | 102 | 0.240 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2010 | 90 | 0.240 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2005 | 60 | 0.240 |
Why?
|
| Blood Pressure | 2 | 2010 | 1363 | 0.230 |
Why?
|
| Perfusion | 5 | 2008 | 205 | 0.230 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2005 | 88 | 0.230 |
Why?
|
| HIV | 3 | 2010 | 180 | 0.230 |
Why?
|
| Dendritic Cells | 6 | 2013 | 411 | 0.230 |
Why?
|
| Nervous System | 1 | 2005 | 127 | 0.230 |
Why?
|
| Neuropeptides | 1 | 2005 | 113 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 5 | 2010 | 1585 | 0.220 |
Why?
|
| RNA Interference | 5 | 2013 | 497 | 0.220 |
Why?
|
| Claudin-1 | 3 | 2009 | 20 | 0.220 |
Why?
|
| Wine | 1 | 2003 | 15 | 0.220 |
Why?
|
| Adenosine Triphosphate | 3 | 2010 | 282 | 0.220 |
Why?
|
| Plant Leaves | 1 | 2004 | 43 | 0.220 |
Why?
|
| Leptin | 1 | 2005 | 214 | 0.220 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 889 | 0.220 |
Why?
|
| Gene Products, gag | 2 | 2001 | 19 | 0.220 |
Why?
|
| Gene Products, tat | 1 | 2003 | 28 | 0.220 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2010 | 97 | 0.220 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 176 | 0.210 |
Why?
|
| Virion | 4 | 2009 | 147 | 0.210 |
Why?
|
| Myography | 3 | 2009 | 10 | 0.210 |
Why?
|
| Catheterization | 2 | 2002 | 234 | 0.210 |
Why?
|
| Fascioliasis | 2 | 2013 | 6 | 0.200 |
Why?
|
| Gene Expression Profiling | 2 | 2009 | 1705 | 0.200 |
Why?
|
| DNA Primers | 4 | 2011 | 657 | 0.200 |
Why?
|
| Enzyme Activation | 5 | 2013 | 622 | 0.200 |
Why?
|
| Neutrophils | 1 | 2005 | 381 | 0.200 |
Why?
|
| Sus scrofa | 4 | 2011 | 127 | 0.200 |
Why?
|
| Progesterone | 1 | 2005 | 623 | 0.200 |
Why?
|
| Occludin | 3 | 2009 | 18 | 0.190 |
Why?
|
| Rheology | 1 | 2002 | 32 | 0.190 |
Why?
|
| Vaccines, Virus-Like Particle | 2 | 2013 | 33 | 0.190 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 48 | 0.190 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 100 | 0.190 |
Why?
|
| Motor Activity | 1 | 2005 | 521 | 0.190 |
Why?
|
| Lymphokines | 1 | 2002 | 66 | 0.190 |
Why?
|
| Receptors, CCR5 | 1 | 2001 | 29 | 0.190 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2013 | 107 | 0.190 |
Why?
|
| Masoprocol | 2 | 2011 | 10 | 0.180 |
Why?
|
| Hypertension | 1 | 2010 | 1324 | 0.180 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 57 | 0.180 |
Why?
|
| Luminescent Measurements | 3 | 2005 | 57 | 0.180 |
Why?
|
| Neointima | 2 | 2011 | 43 | 0.180 |
Why?
|
| Cell Adhesion Molecules | 3 | 2011 | 222 | 0.170 |
Why?
|
| STAT3 Transcription Factor | 4 | 2010 | 220 | 0.170 |
Why?
|
| Viral Envelope Proteins | 1 | 2001 | 152 | 0.170 |
Why?
|
| Neuropilin-1 | 3 | 2010 | 15 | 0.170 |
Why?
|
| Antigens, Neoplasm | 4 | 2011 | 386 | 0.170 |
Why?
|
| Iliac Artery | 4 | 2003 | 93 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2013 | 218 | 0.170 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2011 | 44 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 620 | 0.170 |
Why?
|
| Gene Products, env | 1 | 2000 | 15 | 0.170 |
Why?
|
| Virus Assembly | 1 | 2000 | 47 | 0.170 |
Why?
|
| HIV Infections | 5 | 2012 | 1889 | 0.170 |
Why?
|
| AIDS Vaccines | 3 | 2010 | 30 | 0.160 |
Why?
|
| Umbilical Veins | 3 | 2006 | 73 | 0.160 |
Why?
|
| Proteins | 3 | 2011 | 1036 | 0.160 |
Why?
|
| Extracellular Matrix | 3 | 2014 | 235 | 0.160 |
Why?
|
| Catalase | 2 | 2010 | 50 | 0.160 |
Why?
|
| DNA Damage | 3 | 2012 | 513 | 0.160 |
Why?
|
| Actins | 2 | 2013 | 342 | 0.160 |
Why?
|
| Zonula Occludens-1 Protein | 2 | 2009 | 16 | 0.160 |
Why?
|
| Culture Techniques | 3 | 2003 | 89 | 0.160 |
Why?
|
| NADPH Oxidases | 2 | 2009 | 114 | 0.160 |
Why?
|
| Muscle Contraction | 3 | 2005 | 188 | 0.160 |
Why?
|
| Databases, Nucleic Acid | 2 | 2009 | 70 | 0.150 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 256 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2011 | 361 | 0.150 |
Why?
|
| Carotid Artery, Common | 1 | 1999 | 73 | 0.150 |
Why?
|
| Caveolin 1 | 2 | 2009 | 48 | 0.150 |
Why?
|
| Phosphorylcholine | 1 | 1998 | 26 | 0.150 |
Why?
|
| Antineoplastic Agents | 4 | 2011 | 1686 | 0.150 |
Why?
|
| Immunotoxins | 1 | 1998 | 21 | 0.150 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1998 | 14 | 0.150 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 185 | 0.150 |
Why?
|
| Anions | 2 | 2008 | 18 | 0.150 |
Why?
|
| Femoral Vein | 1 | 1998 | 51 | 0.150 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2008 | 37 | 0.150 |
Why?
|
| Male | 26 | 2013 | 61375 | 0.150 |
Why?
|
| Integrins | 2 | 2008 | 81 | 0.140 |
Why?
|
| Vasodilator Agents | 2 | 2010 | 204 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2013 | 889 | 0.140 |
Why?
|
| Matrix Metalloproteinases | 2 | 2008 | 66 | 0.140 |
Why?
|
| Plant Proteins | 1 | 1998 | 76 | 0.140 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 678 | 0.140 |
Why?
|
| Stents | 7 | 2003 | 890 | 0.140 |
Why?
|
| Up-Regulation | 5 | 2011 | 865 | 0.140 |
Why?
|
| Epidermal Growth Factor | 1 | 1998 | 121 | 0.140 |
Why?
|
| Free Radical Scavengers | 3 | 2012 | 49 | 0.140 |
Why?
|
| Biological Transport | 2 | 2008 | 354 | 0.140 |
Why?
|
| Membrane Glycoproteins | 3 | 2008 | 410 | 0.140 |
Why?
|
| Mutation | 2 | 2011 | 5845 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 2009 | 137 | 0.140 |
Why?
|
| Ischemia | 5 | 2002 | 357 | 0.140 |
Why?
|
| Cell Survival | 5 | 2013 | 807 | 0.140 |
Why?
|
| Dogs | 5 | 1998 | 768 | 0.140 |
Why?
|
| Homeodomain Proteins | 3 | 2011 | 543 | 0.140 |
Why?
|
| Shear Strength | 2 | 2008 | 17 | 0.140 |
Why?
|
| Phosphoproteins | 2 | 2009 | 404 | 0.130 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2014 | 88 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2010 | 49 | 0.130 |
Why?
|
| Arginine | 1 | 1999 | 332 | 0.130 |
Why?
|
| Mice, Knockout | 1 | 2004 | 3718 | 0.130 |
Why?
|
| Time Factors | 6 | 2010 | 6319 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 2 | 2008 | 136 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2009 | 1016 | 0.130 |
Why?
|
| Trans-Activators | 3 | 2011 | 799 | 0.130 |
Why?
|
| Tenascin | 1 | 1996 | 31 | 0.130 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2009 | 101 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 1016 | 0.120 |
Why?
|
| Vascular Patency | 4 | 2005 | 214 | 0.120 |
Why?
|
| Wound Healing | 2 | 2009 | 457 | 0.120 |
Why?
|
| Blood Platelets | 1 | 1998 | 327 | 0.120 |
Why?
|
| Endothelial Protein C Receptor | 2 | 2005 | 7 | 0.120 |
Why?
|
| Capillaries | 2 | 2006 | 66 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2009 | 381 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 3 | 2009 | 1063 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 539 | 0.120 |
Why?
|
| Ginkgolides | 2 | 2012 | 9 | 0.120 |
Why?
|
| RNA | 2 | 2009 | 570 | 0.120 |
Why?
|
| Thrombolytic Therapy | 3 | 2001 | 212 | 0.120 |
Why?
|
| Cell Cycle | 4 | 2010 | 611 | 0.120 |
Why?
|
| Lactones | 2 | 2012 | 38 | 0.120 |
Why?
|
| Angioplasty, Balloon | 3 | 2000 | 172 | 0.120 |
Why?
|
| Click Chemistry | 1 | 2014 | 3 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2009 | 798 | 0.110 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2005 | 62 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2013 | 214 | 0.110 |
Why?
|
| Oxygen | 2 | 2008 | 553 | 0.110 |
Why?
|
| Tumor Burden | 2 | 2013 | 231 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2010 | 2051 | 0.110 |
Why?
|
| Molecular Mimicry | 1 | 2014 | 25 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2006 | 266 | 0.110 |
Why?
|
| Biomarkers | 3 | 2011 | 3069 | 0.110 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 17 | 0.110 |
Why?
|
| Benzaldehydes | 1 | 2013 | 11 | 0.110 |
Why?
|
| Selenium-Binding Proteins | 1 | 2013 | 2 | 0.110 |
Why?
|
| Selenium | 1 | 2013 | 22 | 0.110 |
Why?
|
| Hyperuricemia | 1 | 2013 | 37 | 0.100 |
Why?
|
| Embolization, Therapeutic | 2 | 2008 | 222 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 579 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 469 | 0.100 |
Why?
|
| HIV Protease | 1 | 2012 | 5 | 0.100 |
Why?
|
| Gout Suppressants | 1 | 2013 | 61 | 0.100 |
Why?
|
| Zinc | 1 | 2013 | 128 | 0.100 |
Why?
|
| Anastomosis, Surgical | 3 | 1998 | 174 | 0.100 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2004 | 134 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 205 | 0.100 |
Why?
|
| Cell-Free System | 4 | 2013 | 106 | 0.100 |
Why?
|
| Salicylates | 1 | 2012 | 53 | 0.100 |
Why?
|
| Cyclin E | 2 | 2010 | 30 | 0.100 |
Why?
|
| Urokinase-Type Plasminogen Activator | 3 | 2001 | 40 | 0.100 |
Why?
|
| Mitochondria | 2 | 2009 | 681 | 0.100 |
Why?
|
| Base Sequence | 3 | 2011 | 3090 | 0.100 |
Why?
|
| Graft Rejection | 1 | 1996 | 590 | 0.100 |
Why?
|
| Prognosis | 4 | 2013 | 4631 | 0.100 |
Why?
|
| Electromyography | 2 | 2011 | 165 | 0.100 |
Why?
|
| Hypochlorous Acid | 1 | 2012 | 5 | 0.100 |
Why?
|
| Hydroxyl Radical | 1 | 2012 | 9 | 0.100 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2012 | 23 | 0.100 |
Why?
|
| Immunotherapy, Active | 2 | 2011 | 18 | 0.100 |
Why?
|
| Larrea | 1 | 2011 | 5 | 0.100 |
Why?
|
| Genes, Switch | 1 | 2011 | 10 | 0.090 |
Why?
|
| Benzyl Alcohols | 1 | 2011 | 15 | 0.090 |
Why?
|
| Klinefelter Syndrome | 1 | 2011 | 16 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2013 | 154 | 0.090 |
Why?
|
| Human Genome Project | 1 | 2011 | 55 | 0.090 |
Why?
|
| CD146 Antigen | 1 | 2011 | 7 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2003 | 806 | 0.090 |
Why?
|
| BRCA1 Protein | 1 | 2011 | 68 | 0.090 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2011 | 42 | 0.090 |
Why?
|
| Gold | 1 | 2011 | 48 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 173 | 0.090 |
Why?
|
| Metal Nanoparticles | 1 | 2011 | 41 | 0.090 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2011 | 87 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 394 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 157 | 0.090 |
Why?
|
| Water Microbiology | 1 | 2010 | 25 | 0.090 |
Why?
|
| Vibrio cholerae | 1 | 2010 | 26 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 184 | 0.090 |
Why?
|
| Testicular Neoplasms | 1 | 2011 | 132 | 0.090 |
Why?
|
| Lipids | 1 | 2013 | 518 | 0.080 |
Why?
|
| Equol | 1 | 2009 | 4 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 2513 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 3 | 2004 | 577 | 0.080 |
Why?
|
| Phytoestrogens | 1 | 2009 | 16 | 0.080 |
Why?
|
| Receptors, CCR3 | 1 | 2009 | 5 | 0.080 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 87 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 242 | 0.080 |
Why?
|
| Probability | 2 | 2007 | 320 | 0.080 |
Why?
|
| NADPH Oxidase 4 | 1 | 2009 | 15 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2002 | 1230 | 0.080 |
Why?
|
| Genetic Therapy | 4 | 2009 | 681 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 1326 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2009 | 691 | 0.080 |
Why?
|
| Catheterization, Peripheral | 2 | 2001 | 125 | 0.080 |
Why?
|
| Aorta, Abdominal | 2 | 2003 | 124 | 0.080 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 288 | 0.080 |
Why?
|
| Colorectal Neoplasms | 3 | 2011 | 574 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 336 | 0.080 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2009 | 11 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 177 | 0.080 |
Why?
|
| Alkynes | 1 | 2009 | 26 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2010 | 777 | 0.080 |
Why?
|
| Targeted Gene Repair | 1 | 2009 | 3 | 0.080 |
Why?
|
| Untranslated Regions | 1 | 2009 | 8 | 0.080 |
Why?
|
| Survival Rate | 2 | 2011 | 2060 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 139 | 0.080 |
Why?
|
| Polyglycolic Acid | 1 | 2009 | 27 | 0.080 |
Why?
|
| SAIDS Vaccines | 1 | 2009 | 6 | 0.080 |
Why?
|
| Tissue Banks | 1 | 2009 | 27 | 0.080 |
Why?
|
| Cyclopropanes | 1 | 2009 | 68 | 0.080 |
Why?
|
| Risk Factors | 3 | 2014 | 10281 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 3 | 2006 | 1031 | 0.080 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2009 | 59 | 0.080 |
Why?
|
| Copper-transporting ATPases | 1 | 2009 | 23 | 0.080 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2008 | 12 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2009 | 71 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2009 | 253 | 0.080 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 137 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2011 | 212 | 0.080 |
Why?
|
| Anus Neoplasms | 1 | 2009 | 38 | 0.080 |
Why?
|
| U937 Cells | 1 | 2008 | 25 | 0.080 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2008 | 36 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2010 | 325 | 0.080 |
Why?
|
| Plasma Cells | 1 | 2009 | 55 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 120 | 0.080 |
Why?
|
| Protein Binding | 2 | 2013 | 1734 | 0.080 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 41 | 0.080 |
Why?
|
| Mutagenesis | 1 | 2010 | 345 | 0.080 |
Why?
|
| Kinetics | 2 | 2007 | 1323 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 488 | 0.080 |
Why?
|
| RNA Stability | 1 | 2009 | 84 | 0.080 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 69 | 0.080 |
Why?
|
| Basigin | 2 | 2005 | 14 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2008 | 49 | 0.080 |
Why?
|
| Genetic Techniques | 1 | 2009 | 106 | 0.080 |
Why?
|
| Collagen | 2 | 2009 | 315 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2009 | 153 | 0.080 |
Why?
|
| Antibodies | 2 | 2011 | 374 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2008 | 18 | 0.080 |
Why?
|
| Kaempferols | 1 | 2008 | 5 | 0.070 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2009 | 138 | 0.070 |
Why?
|
| Neuropilin-2 | 1 | 2008 | 9 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2008 | 19 | 0.070 |
Why?
|
| NADP | 1 | 2008 | 49 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 237 | 0.070 |
Why?
|
| Nifedipine | 1 | 2008 | 21 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2009 | 121 | 0.070 |
Why?
|
| Surgical Stapling | 1 | 2008 | 19 | 0.070 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 115 | 0.070 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 136 | 0.070 |
Why?
|
| Thrombosis | 2 | 2005 | 522 | 0.070 |
Why?
|
| Sphingomyelins | 1 | 2007 | 15 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2008 | 50 | 0.070 |
Why?
|
| Neurogenesis | 1 | 2009 | 189 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 115 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2008 | 89 | 0.070 |
Why?
|
| Vaccination | 2 | 2013 | 955 | 0.070 |
Why?
|
| Genes, Dominant | 1 | 2008 | 245 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2009 | 131 | 0.070 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2007 | 48 | 0.070 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2007 | 7 | 0.070 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2007 | 42 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 1492 | 0.070 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2007 | 12 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2008 | 176 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 419 | 0.070 |
Why?
|
| Forecasting | 2 | 2011 | 351 | 0.070 |
Why?
|
| Disease Progression | 3 | 2008 | 2058 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 6 | 2013 | 4375 | 0.070 |
Why?
|
| Female | 14 | 2013 | 66655 | 0.070 |
Why?
|
| Multienzyme Complexes | 1 | 2007 | 88 | 0.070 |
Why?
|
| Carcinoma | 1 | 2009 | 287 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2008 | 209 | 0.070 |
Why?
|
| Renal Dialysis | 3 | 2005 | 852 | 0.070 |
Why?
|
| Postoperative Complications | 3 | 2004 | 3069 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 96 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2007 | 185 | 0.070 |
Why?
|
| Stimulation, Chemical | 1 | 2006 | 65 | 0.060 |
Why?
|
| Rats | 4 | 2002 | 3676 | 0.060 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2006 | 25 | 0.060 |
Why?
|
| Radiography | 6 | 2008 | 820 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 642 | 0.060 |
Why?
|
| Regeneration | 1 | 2008 | 198 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2006 | 63 | 0.060 |
Why?
|
| Leukocytes | 1 | 2007 | 205 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 2009 | 333 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 436 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 41 | 0.060 |
Why?
|
| Selenium Compounds | 1 | 2005 | 3 | 0.060 |
Why?
|
| Nelfinavir | 1 | 2005 | 5 | 0.060 |
Why?
|
| Laminin | 1 | 2006 | 69 | 0.060 |
Why?
|
| Indinavir | 1 | 2005 | 6 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2006 | 88 | 0.060 |
Why?
|
| Saquinavir | 1 | 2005 | 6 | 0.060 |
Why?
|
| Vasculitis | 1 | 2005 | 49 | 0.060 |
Why?
|
| Furans | 1 | 2005 | 28 | 0.060 |
Why?
|
| Carbamates | 1 | 2005 | 60 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2005 | 59 | 0.060 |
Why?
|
| Integrin alpha4 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Organ Culture Techniques | 1 | 2005 | 155 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2005 | 146 | 0.060 |
Why?
|
| Thymidine Kinase | 1 | 2005 | 95 | 0.060 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2005 | 44 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2011 | 1002 | 0.060 |
Why?
|
| Pancreatic Ducts | 1 | 2004 | 21 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2007 | 536 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2005 | 90 | 0.060 |
Why?
|
| Adiponectin | 1 | 2005 | 114 | 0.060 |
Why?
|
| Reassortant Viruses | 1 | 2004 | 34 | 0.060 |
Why?
|
| Cell Death | 2 | 2012 | 240 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2005 | 58 | 0.060 |
Why?
|
| Cadherins | 1 | 2005 | 166 | 0.060 |
Why?
|
| Umbilical Cord | 1 | 2004 | 56 | 0.060 |
Why?
|
| Renal Artery | 3 | 2008 | 76 | 0.060 |
Why?
|
| Materials Testing | 2 | 2009 | 73 | 0.060 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2004 | 21 | 0.060 |
Why?
|
| E-Selectin | 1 | 2004 | 41 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2013 | 682 | 0.060 |
Why?
|
| Pericardium | 1 | 2005 | 81 | 0.060 |
Why?
|
| Software | 1 | 2009 | 683 | 0.060 |
Why?
|
| Monocytes | 2 | 2007 | 351 | 0.060 |
Why?
|
| Islets of Langerhans | 1 | 2005 | 172 | 0.060 |
Why?
|
| Protein Folding | 1 | 2005 | 216 | 0.060 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 22 | 0.050 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 314 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 669 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1182 | 0.050 |
Why?
|
| ErbB Receptors | 2 | 2011 | 281 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2005 | 267 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2004 | 186 | 0.050 |
Why?
|
| Analgesia, Epidural | 1 | 2003 | 28 | 0.050 |
Why?
|
| Culture Media | 1 | 2003 | 182 | 0.050 |
Why?
|
| Organ Preservation Solutions | 2 | 2009 | 16 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1697 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 305 | 0.050 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2003 | 42 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 195 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 3877 | 0.050 |
Why?
|
| Epigastric Arteries | 1 | 2002 | 7 | 0.050 |
Why?
|
| Stroke | 1 | 2011 | 987 | 0.050 |
Why?
|
| Transfection | 3 | 2010 | 1062 | 0.050 |
Why?
|
| Vena Cava Filters | 1 | 2002 | 21 | 0.050 |
Why?
|
| Random Allocation | 1 | 2003 | 436 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2002 | 45 | 0.050 |
Why?
|
| Embolism, Cholesterol | 1 | 2002 | 3 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1548 | 0.050 |
Why?
|
| Iliac Aneurysm | 1 | 2002 | 31 | 0.050 |
Why?
|
| Pelvis | 1 | 2002 | 71 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2002 | 106 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2005 | 375 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 710 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2008 | 767 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 169 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2002 | 61 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2013 | 1507 | 0.050 |
Why?
|
| Concanavalin A | 1 | 2001 | 16 | 0.050 |
Why?
|
| Acetylcholine | 1 | 2002 | 83 | 0.050 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2001 | 6 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2004 | 356 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 649 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2002 | 175 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2011 | 503 | 0.050 |
Why?
|
| Genes, Reporter | 2 | 2013 | 380 | 0.050 |
Why?
|
| Endoscopy | 1 | 2003 | 280 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2008 | 940 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 457 | 0.050 |
Why?
|
| Angioplasty | 1 | 2001 | 89 | 0.050 |
Why?
|
| Arteriovenous Fistula | 1 | 2001 | 57 | 0.050 |
Why?
|
| General Surgery | 1 | 2003 | 206 | 0.050 |
Why?
|
| Thrombophlebitis | 1 | 2001 | 22 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2002 | 324 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2005 | 851 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2001 | 133 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2001 | 107 | 0.040 |
Why?
|
| Hematoma | 1 | 2001 | 93 | 0.040 |
Why?
|
| Lung | 2 | 2006 | 1488 | 0.040 |
Why?
|
| Plasminogen Activators | 1 | 2000 | 20 | 0.040 |
Why?
|
| Aneurysm, False | 1 | 2001 | 104 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 931 | 0.040 |
Why?
|
| S Phase | 2 | 2011 | 73 | 0.040 |
Why?
|
| Cell Fusion | 1 | 2000 | 37 | 0.040 |
Why?
|
| Cyclin D1 | 2 | 2010 | 112 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2003 | 674 | 0.040 |
Why?
|
| Neurons | 1 | 2009 | 1922 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 2005 | 877 | 0.040 |
Why?
|
| Aortic Diseases | 1 | 2002 | 199 | 0.040 |
Why?
|
| Carotid Stenosis | 1 | 2000 | 143 | 0.040 |
Why?
|
| Kidney | 2 | 1996 | 1356 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 1116 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2010 | 374 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 254 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2002 | 540 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 1314 | 0.040 |
Why?
|
| Immunization | 2 | 2011 | 307 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 1998 | 60 | 0.040 |
Why?
|
| Antimetabolites | 1 | 1998 | 32 | 0.040 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 1998 | 1 | 0.040 |
Why?
|
| Tyrphostins | 2 | 2008 | 13 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 472 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2011 | 503 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2001 | 468 | 0.040 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 1998 | 14 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2000 | 806 | 0.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 1998 | 58 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2000 | 461 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 1998 | 258 | 0.040 |
Why?
|
| HIV Antibodies | 2 | 2010 | 69 | 0.040 |
Why?
|
| Hand | 1 | 1998 | 100 | 0.030 |
Why?
|
| Silicone Elastomers | 1 | 1996 | 35 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2010 | 568 | 0.030 |
Why?
|
| Jugular Veins | 1 | 1997 | 77 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2003 | 596 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 1240 | 0.030 |
Why?
|
| Allopurinol | 2 | 2013 | 71 | 0.030 |
Why?
|
| T-Lymphocytes | 3 | 2010 | 1707 | 0.030 |
Why?
|
| Antigen Presentation | 2 | 2007 | 104 | 0.030 |
Why?
|
| Cardioplegic Solutions | 1 | 1996 | 17 | 0.030 |
Why?
|
| Renal Circulation | 1 | 1996 | 46 | 0.030 |
Why?
|
| Graft Survival | 1 | 1998 | 536 | 0.030 |
Why?
|
| Aged | 6 | 2013 | 19825 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2000 | 592 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 1996 | 104 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 2582 | 0.030 |
Why?
|
| Biocompatible Materials | 2 | 2009 | 118 | 0.030 |
Why?
|
| Glutathione | 2 | 2011 | 193 | 0.030 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Valosin Containing Protein | 1 | 2013 | 6 | 0.030 |
Why?
|
| Catechols | 1 | 2013 | 9 | 0.030 |
Why?
|
| Molybdenum | 1 | 2013 | 15 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2013 | 8 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2013 | 27 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 77 | 0.030 |
Why?
|
| Organoselenium Compounds | 1 | 2013 | 5 | 0.030 |
Why?
|
| Azetidines | 1 | 2013 | 58 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 58 | 0.030 |
Why?
|
| Middle Aged | 5 | 2013 | 26867 | 0.030 |
Why?
|
| Simvastatin | 1 | 2013 | 76 | 0.030 |
Why?
|
| Ezetimibe | 1 | 2013 | 95 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 229 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 2043 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2013 | 211 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2003 | 1175 | 0.030 |
Why?
|
| Heterografts | 1 | 2013 | 172 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 238 | 0.030 |
Why?
|
| Uric Acid | 1 | 2013 | 94 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 113 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2013 | 179 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2012 | 78 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 574 | 0.020 |
Why?
|
| Luciferases, Renilla | 1 | 2011 | 3 | 0.020 |
Why?
|
| Cyclin A | 1 | 2011 | 17 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2011 | 16 | 0.020 |
Why?
|
| Chromones | 1 | 2011 | 22 | 0.020 |
Why?
|
| Coumarins | 1 | 2011 | 23 | 0.020 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2011 | 27 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 61 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 132 | 0.020 |
Why?
|
| Morpholines | 1 | 2011 | 57 | 0.020 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2011 | 42 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 354 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 351 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 440 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 78 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 55 | 0.020 |
Why?
|
| Estrogens | 1 | 2013 | 499 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 152 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 330 | 0.020 |
Why?
|
| Papio | 2 | 2003 | 60 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 355 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 368 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2011 | 188 | 0.020 |
Why?
|
| Catheters, Indwelling | 2 | 2004 | 154 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2003 | 153 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2010 | 140 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 2 | 2003 | 192 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 173 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 130 | 0.020 |
Why?
|
| Genes, bcl-1 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Treatment Outcome | 5 | 2004 | 12398 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2009 | 42 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 502 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1642 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 795 | 0.020 |
Why?
|
| Leukosialin | 1 | 2009 | 4 | 0.020 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2009 | 14 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2009 | 88 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 57 | 0.020 |
Why?
|
| Germinal Center | 1 | 2009 | 38 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 794 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2009 | 54 | 0.020 |
Why?
|
| Absorbable Implants | 1 | 2009 | 25 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1278 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2009 | 32 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 2009 | 36 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 878 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2009 | 48 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2009 | 90 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2009 | 65 | 0.020 |
Why?
|
| Teratogens | 1 | 2009 | 88 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 119 | 0.020 |
Why?
|
| P-Selectin | 1 | 2009 | 78 | 0.020 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2009 | 58 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 723 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2009 | 81 | 0.020 |
Why?
|
| Equipment Design | 2 | 2004 | 596 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2008 | 31 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2009 | 80 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 292 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 212 | 0.020 |
Why?
|
| Confidentiality | 1 | 2009 | 99 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2009 | 266 | 0.020 |
Why?
|
| Polyvinyl Alcohol | 1 | 2008 | 10 | 0.020 |
Why?
|
| Cobalt | 1 | 2008 | 17 | 0.020 |
Why?
|
| Platinum | 1 | 2008 | 12 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2009 | 142 | 0.020 |
Why?
|
| ras Proteins | 1 | 2009 | 137 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 301 | 0.020 |
Why?
|
| Epinephrine | 1 | 2009 | 181 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 736 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 157 | 0.020 |
Why?
|
| Splenic Artery | 1 | 2008 | 26 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 95 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 279 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2008 | 89 | 0.020 |
Why?
|
| Papillomavirus Vaccines | 1 | 2009 | 94 | 0.020 |
Why?
|
| Splenectomy | 1 | 2008 | 64 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 128 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2009 | 448 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 51 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2010 | 280 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 80 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 107 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2009 | 439 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 293 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 249 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2009 | 473 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2009 | 229 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2008 | 357 | 0.020 |
Why?
|
| Informed Consent | 1 | 2009 | 334 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 375 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 2 | 1996 | 73 | 0.020 |
Why?
|
| Incidence | 2 | 2004 | 3138 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2007 | 132 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2004 | 16336 | 0.020 |
Why?
|
| Exonucleases | 1 | 2005 | 23 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2005 | 64 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 73 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 293 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2005 | 45 | 0.010 |
Why?
|
| Exoribonucleases | 1 | 2005 | 23 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2005 | 56 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2703 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 2005 | 52 | 0.010 |
Why?
|
| Hypoalbuminemia | 1 | 2004 | 18 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 250 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 2005 | 54 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 394 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2004 | 5163 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2004 | 231 | 0.010 |
Why?
|
| Liposomes | 1 | 2005 | 178 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 285 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2009 | 815 | 0.010 |
Why?
|
| Computational Biology | 1 | 2009 | 810 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 1532 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 303 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 256 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 512 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 415 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 2005 | 317 | 0.010 |
Why?
|
| Vital Capacity | 1 | 2003 | 76 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 1757 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2009 | 1151 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2003 | 171 | 0.010 |
Why?
|
| Prevalence | 1 | 2009 | 2448 | 0.010 |
Why?
|
| Foreign-Body Migration | 1 | 2002 | 72 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2002 | 87 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3569 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 429 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 606 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2004 | 172 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2002 | 6148 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1660 | 0.010 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2000 | 4 | 0.010 |
Why?
|
| Leg | 1 | 2002 | 158 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1439 | 0.010 |
Why?
|
| Iliac Vein | 1 | 2001 | 34 | 0.010 |
Why?
|
| United States | 2 | 2009 | 10906 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 226 | 0.010 |
Why?
|
| Adult | 2 | 2004 | 29562 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2000 | 17 | 0.010 |
Why?
|
| Alloys | 1 | 2000 | 16 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 2635 | 0.010 |
Why?
|
| Pneumonia | 1 | 2003 | 323 | 0.010 |
Why?
|
| Angiography | 1 | 2000 | 215 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 696 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2000 | 158 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 1108 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1737 | 0.010 |
Why?
|
| Critical Care | 1 | 2003 | 656 | 0.010 |
Why?
|
| Length of Stay | 1 | 2003 | 1311 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2001 | 1190 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 1165 | 0.010 |
Why?
|
| Stainless Steel | 1 | 1997 | 6 | 0.010 |
Why?
|
| Goats | 1 | 1997 | 55 | 0.010 |
Why?
|
| Venous Insufficiency | 1 | 1997 | 12 | 0.010 |
Why?
|
| Porosity | 1 | 1996 | 38 | 0.010 |
Why?
|
| Surface Properties | 1 | 1996 | 81 | 0.010 |
Why?
|
| Smoking | 1 | 2002 | 1045 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 2902 | 0.010 |
Why?
|
| Raffinose | 1 | 1996 | 6 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2003 | 998 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1996 | 15 | 0.010 |
Why?
|
| Hypertonic Solutions | 1 | 1996 | 20 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3287 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1996 | 35 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1996 | 94 | 0.010 |
Why?
|
| Body Temperature | 1 | 1996 | 116 | 0.010 |
Why?
|
| Rectum | 1 | 1996 | 100 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 4805 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 3448 | 0.010 |
Why?
|
| Adenosine | 1 | 1996 | 126 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1996 | 427 | 0.010 |
Why?
|
| Age Factors | 1 | 2001 | 2822 | 0.010 |
Why?
|
| Organ Size | 1 | 1996 | 431 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 1996 | 170 | 0.010 |
Why?
|
| Creatinine | 1 | 1996 | 390 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1997 | 759 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1996 | 377 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1996 | 679 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 6583 | 0.010 |
Why?
|
| Insulin | 1 | 1996 | 1201 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2001 | 8199 | 0.000 |
Why?
|
| Infant | 1 | 2001 | 12473 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2001 | 14018 | 0.000 |
Why?
|
| Adolescent | 1 | 2001 | 19336 | 0.000 |
Why?
|
| Child | 1 | 2001 | 24399 | 0.000 |
Why?
|